Advances in Target-Based Drug Discovery: A Spotlight on Optical Biosensors

Advances in Target-Based Drug Discovery: A Spotlight on Optical BiosensorsOptical biosensor techniques like surface plasmon resonance (SPR) or biolayer interferometry (BLI) have been successfully applied in target-based drug discovery for more than 25 years. These technologies are now considered key biophysical approaches in drug discovery programs due to their high sensitivity and robustness, and allow for the characterization of a variety of molecular interactions of different complexity. This webinar will explore the key applications of optical biosensor approaches in target-based drug discovery through a series of case studies, and dive into the latest advancements and future opportunities for these techniques. 1. The key applications of optical biosensors in target-based drug discovery 2. The technology-based limitations of optical biosensors 3. The recent developments in optical biosensor technology how optical biosensor approaches can evolve in future 4. How optical biosensor approaches may evolve in future Florian Krieger, PhD VP Biophysics evotec Dr Krieger holds a Diploma in Biochemistry from the University of Halle (2000) with a focus on enzymology and obtained his Ph.D. in Biophysical Chemistry from the University of Basel (2004) in the field of protein folding. He then spent three years as a postdoctoral fellow at Louis Pasteur University Strasbourg studying the modulation of nicotinic acetylcholine receptor by small molecules. In 2008 he joined Evotec as a Research Scientist and became member of the he biochemical Assay Development group. Since this time, he gained experiences in small molecule HTS approaches but also contributed to the setup of Evotec’s biophysics platform. Since 2022 Dr Krieger is heading the biophysics unit at Evotec Hamburg site as VP Biophysics.